Advanced Sterilization Products (ASP) Announces CE Mark for ULTRA GI™ Cycle for Duodenoscopes in Partnership with FUJIFILM Healthcare Europe

Rhea-AI Summary

Advanced Sterilization Products (FTV) announced on Jan 15, 2026 that the ULTRA GI™ Cycle for the STERRAD™ 100NX Sterilizer with ALLClear™ Technology received CE mark approval in partnership with FUJIFILM Healthcare Europe. The cycle adds hydrogen peroxide gas plasma sterilization for duodenoscopes, including compatibility for FUJIFILM models ED-840T and ED-840XT. Existing STERRAD 100NX customers can obtain the ULTRA GI Cycle via a cycle upgrade on installed equipment, while ASP will work with device makers to design future duodenoscopes for hydrogen peroxide compatibility. The move aims to strengthen reprocessing confidence and patient safety across European healthcare settings.

Positive

• ULTRA GI Cycle received CE mark approval (Jan 15, 2026)
• Adds hydrogen peroxide gas plasma sterilization for duodenoscopes
• FUJIFILM models ED-840T and ED-840XT added to approved cycle
• Existing STERRAD 100NX units eligible for cycle upgrade

Negative

• Approval is limited to CE mark jurisdiction—Europe
• Requires duodenoscopes to be designed for hydrogen peroxide compatibility

Key Figures

STERRAD 100NX model: 100NX

1 metrics

STERRAD 100NX model 100NX Model designation of the STERRAD 100NX Sterilizer mentioned in the release

Market Reality Check

Price: $55.51 Vol: Volume 2,824,516 vs 20-da...

normal vol

$55.51 Last Close

Volume Volume 2,824,516 vs 20-day average 3,369,922 (relative volume 0.84x). normal

Technical Price 55.76 is above 200-day MA at 51.36, and 11.19% below 52-week high 62.7882.

Peers on Argus

FTV was up 1.98% with mixed peer moves: TDY up 1.36%, KEYS slightly positive, wh...

2 Up

FTV was up 1.98% with mixed peer moves: TDY up 1.36%, KEYS slightly positive, while COHR and GRMN were down on the day. Momentum scanner showed COHR and MKSI moving up without related news, suggesting stock-specific rather than sector-wide drivers.

Historical Context

5 past events · Latest: Jan 07 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 07	Earnings call setup	Neutral	+2.0%	Scheduled Q4 2025 earnings webcast and provided access details for investors.
Jan 06	Board appointment (peer)	Neutral	+3.0%	Board appointment at Tolion Health AI highlighting director’s roles including Fortive.
Nov 03	Product launch	Neutral	-0.5%	Launch of CalStudio SaaS calibration-management platform under Fluke (FTV).
Oct 31	Conference appearance	Neutral	-1.8%	CEO presentation announcement for Baird 2025 Global Industrial Conference.
Oct 30	Industry survey	Neutral	+1.8%	Fluke survey on unplanned downtime costs and vulnerabilities in manufacturing.

Pattern Detected

Recent Fortive news has generally produced modest single-day moves, with both positive and negative reactions to largely informational announcements.

Recent Company History

Over the past few months, Fortive has focused on investor communications and product innovation. An earnings call was scheduled for Feb 4, 2026 with a prior +1.98% move. Earlier, Fluke (FTV) launched the CalStudio SaaS platform on Nov 3, 2025 with a slight negative reaction. Conference participation on Nov 11, 2025 and survey-based insights into unplanned downtime on Oct 30, 2025 saw small price moves, underscoring a pattern of modest reactions to operational news.

Market Pulse Summary

This announcement highlights a CE-marked ULTRA GI Cycle for duodenoscopes on the STERRAD 100NX platf...

Analysis

This announcement highlights a CE-marked ULTRA GI Cycle for duodenoscopes on the STERRAD 100NX platform, emphasizing infection control and patient safety in partnership with FUJIFILM Healthcare Europe. For context, Fortive has recently focused on product innovation and investor outreach, including new software platforms and scheduled earnings calls. Investors may track adoption of this sterilization technology, future regulatory milestones, and subsequent product or partnership updates as indicators of the initiative’s strategic impact.

Key Terms

ce mark, duodenoscopes, hydrogen peroxide gas plasma sterilization, reprocessing, +2 more

6 terms

ce mark regulatory

"ULTRA GI™ Cycle has received CE mark approval."

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

duodenoscopes medical

"CE Mark for ULTRA GI™ Cycle for Duodenoscopes in Partnership"

A duodenoscope is a long, flexible medical camera used by doctors to look into and treat the first part of the small intestine and nearby ducts, similar to threading a tiny inspection camera through a narrow pipe. Investors care because these devices are regulated, can carry safety and infection risks that trigger recalls or redesigns, and represent recurring revenue from sales, servicing and replacements that affect manufacturers’ and hospitals’ finances.

hydrogen peroxide gas plasma sterilization medical

"By bringing hydrogen peroxide gas plasma sterilization into routine practice"

Hydrogen peroxide gas plasma sterilization is a low‑temperature process that uses vaporized hydrogen peroxide and an energized (plasma) field to kill bacteria, viruses and spores on medical devices without heat or harsh chemicals. Think of it as a cold, fast “steam cleaning” for delicate instruments that would be damaged by baking. Investors care because the method affects product approval, hospital purchasing, operating costs and the market for sterilization equipment and consumables.

reprocessing medical

"make duodenoscope reprocessing safer across Europe"

Reprocessing is the cleaning, inspection, repair if needed, and sterilization of medical products so they can be safely used again instead of being thrown away. Think of it like washing and refurbishing a kitchen tool so it’s safe and functional for the next use. Investors care because reprocessing affects costs, regulatory approvals, liability and long-term demand for single‑use versus reusable products, all of which influence company profits and risk.

infection control medical

"Duodenoscopes have historically posed infection control challenges"

Infection control is the set of practices and policies that prevent the spread of germs and disease in places like hospitals, workplaces, and public spaces. It matters to investors because strong infection control reduces the risk of costly outbreaks, regulatory fines, and reputational damage, while increasing demand for related products and services (such as protective equipment, cleaning technologies, and training)—think of it like traffic rules that keep a busy system running safely and predictably.

contamination rates medical

"posed infection control challenges due to their contamination rates"

Contamination rates measure the share of products, samples or shipments that contain unwanted substances, microbes or impurities during manufacturing, testing or distribution. Investors watch them because higher rates can trigger recalls, regulatory penalties, production delays and extra cleanup costs, all of which reduce revenue and damage reputation—similar to finding a sizable portion of a fruit batch spoiled and unsellable, forcing the seller to absorb losses and repair trust.

AI-generated analysis. Not financial advice.

New cycle for the STERRAD™ 100NX Sterilizer expands sterilization options, enhances reprocessing confidence, and promotes patient safety.

SCHAFFHAUSEN, Switzerland, Jan. 15, 2026 /PRNewswire/ -- ASP GmbH ("ASP"), a division of Fortive (NYSE: FTV), in collaboration with FUJIFILM Healthcare Europe GmbH, proudly announces that the ULTRA GI™ Cycle has received CE mark approval. The ULTRA GI™ Cycle is the latest innovation for the STERRAD™ 100NX Sterilizer with ALLClear™ Technology.

The ULTRA GI™ Cycle's receipt of the CE mark represents a pivotal advancement in elevating patient safety across healthcare facilities and addressing the complex challenges associated with traditional reprocessing methods. "This is a meaningful step forward in our mission to make duodenoscope reprocessing safer across Europe," said Chad Rohrer, President, ASP. "By bringing hydrogen peroxide gas plasma sterilization into routine practice, we're giving clinicians greater confidence to focus on what matters most – their patients." ASP's immediate focus is to work with medical device manufacturers to ensure that new duodenoscope models are designed to be compatible with hydrogen peroxide. The partnership with FUJIFILM Healthcare Europe is the latest example of this.

Pierre Emeric, Vice President, R&D at ASP continued, "The addition of the new FUJIFILM duodenoscope models ED-840T and ED-840XT to the ULTRA GI Cycle further expands the breakthrough technology platform and demonstrates ASP's commitment to innovation and partnership with FUJIFILM Healthcare. Most importantly, current ASP customers who already have a STERRAD 100NX Sterilizer with ALLClear Technology can access the benefits of the ULTRA GI Cycle via a cycle upgrade on their existing equipment and can continue maximizing the value of their investment."

"Duodenoscopes have historically posed infection control challenges due to their contamination rates," said Ivan Salgo, MD, VP & Chief Medical Officer at ASP. "The partnership between ASP and FUJIFILM Healthcare has resulted in a sterilization approach that exceeds current industry benchmarks, providing healthcare professionals with an advanced solution to elevate patient safety standards."

Visit this webpage for more information on the ULTRA GI™ Cycle.

For media inquiries or further information, please contact:

MEDIA CONTACT:
Nuno Azeredo
Vice President, Global Brand Marketing
Advanced Sterilization Products (ASP) 
asp-communications@asp.com 

INVESTOR RELATIONS:
Christina Jones
Vice President, Investor Relations
Fortive Corporation
investors@fortive.com

About Advanced Sterilization Products (ASP)
Advanced Sterilization Products (ASP) has a long track record of designing and delivering innovative infection prevention solutions that dramatically raise the level of health care and safety for those who matter most. Our pioneering technology, global distribution and established leadership position enable us to simplify the process of buying and operating infection prevention products and services every day for thousands of medical facilities around the world. This enables our customers to focus on what they do best – preventing infection and saving lives. For more information, please visit www.asp.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/advanced-sterilization-products-asp-announces-ce-mark-for-ultra-gi-cycle-for-duodenoscopes-in-partnership-with-fujifilm-healthcare-europe-302661858.html

SOURCE Advanced Sterilization Products (ASP)

FAQ

What did ASP (FTV) announce on January 15, 2026 about the ULTRA GI Cycle?

ASP announced the ULTRA GI Cycle for STERRAD 100NX received a CE mark and is available via cycle upgrade.

Which FUJIFILM duodenoscope models are compatible with the ULTRA GI Cycle?

The ULTRA GI Cycle includes compatibility for FUJIFILM duodenoscopes ED-840T and ED-840XT.

Can current STERRAD 100NX owners access the ULTRA GI Cycle on installed equipment?

Yes. Current STERRAD 100NX customers can access the ULTRA GI Cycle through a cycle upgrade on existing units.

What sterilization method does the ULTRA GI Cycle use for duodenoscopes?

The ULTRA GI Cycle uses hydrogen peroxide gas plasma sterilization to reprocess duodenoscopes.

Does the ULTRA GI CE mark apply worldwide or only in Europe for FTV?

The announcement specifies a CE mark, which applies to European jurisdictions; other regions are not referenced.